Two pools were formed including: (1) plasma samples that displayed the highest binding to FcγR2B (mean fluorescent intensity (MFI) > 104) but not FcγR3B (MFI < 104), found largely in vaccinees who ultimately developed COVID-19 (COVID-19+FcR2B+3B−) (pool of n = 5) and (2) plasma samples with the most robust binding to FcγR3B (MFI > 104) and lacking binding to FcγR2B (MFI < 104), vastly enriched in vaccinees who resisted COVID-19 for the study period (COVID-19−FcR2B−3B+) (pool of n = 5) (Fig. 5a). This evidence concerns the gene FCGR2B and COVID-19.